keyword
MENU ▼
Read by QxMD icon Read
search

cancer and venous thromboembolism

keyword
https://www.readbyqxmd.com/read/28078351/outcomes-of-low-molecular-weight-heparin-treatment-for-venous-thromboembolism-in-patients-with-primary-and-metastatic-brain-tumours
#1
Chatree Chai-Adisaksopha, Lori-Ann Linkins, Said Y ALKindi, Matthew Cheah, Mark A Crowther, Alfonso Iorio
Venous thromboembolism (VTE) is one of the most common complications in patients with brain tumours. There is limited data available in the literature on VTE treatment in these patients. We conducted a matched retrospective cohort study of patients with primary or metastatic brain cancer who were diagnosed with cancer-associated VTE. Patients were selected after a retrospective chart review of consecutive patients who were diagnosed with cancer-associated VTE between January 2010 and January 2014 at the Juravinski Thrombosis Clinic, Hamilton, Canada...
January 12, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28077689/giant-cell-arteritis-and-vascular-disease-risk-factors-and-outcomes-a-cohort-study-using-uk-clinical-practice-research-datalink
#2
Lin Li, Tuhina Neogi, Susan Jick
OBJECTIVE: To evaluate the associations between GCA and vascular diseases and other comorbidities in patients with GCA compared with non-vasculitis patients. METHODS: Using the UK-based Clinical Practice Research Datalink we identified 9778 newly diagnosed GCA patients in 1990-2014, and up to 10 non-vasculitis patients randomly matched to each case on age, sex, practice and years of history before cohort entry. We compared the distributions of 9 different pre-existing vascular diseases and 11 other comorbidities, and risks of incident vascular diseases and other comorbidities after cohort entry between GCA and non-vasculitis patients...
January 11, 2017: Rheumatology
https://www.readbyqxmd.com/read/28075424/managing-challenging-patients-with-venous-thromboembolism-a-practical-case-based-approach
#3
James Douketis, Walter Ageno, Marc Carrier, Clive Kearon
The management of patients with venous thromboembolism is a common clinical scenario that, for the most part, involves well-established, evidence-based treatment pathways. However, important unanswered clinical questions remain that are the focus of ongoing research. The aim of this narrative review is to provide a practical, case-based approach to the following clinical scenarios in which therapeutic management pathways are less well established: How long to anticoagulated patients with a first unprovoked venous thromboembolism? How to manage complex patients with cancer-associated venous thromboembolism? When and how to treat patients with splanchnic vein thrombosis? When to use thrombolytic therapy for deep vein thrombosis?...
January 4, 2017: Polskie Archiwum Medycyny Wewnętrznej
https://www.readbyqxmd.com/read/28073783/podoplanin-expression-in-primary-brain-tumors-induces-platelet-aggregation-and-increases-risk-of-venous-thromboembolism
#4
Julia Riedl, Matthias Preusser, Pegah Mir Seyed Nazari, Florian Posch, Simon Panzer, Christine Marosi, Peter Birner, Johannes Thaler, Christine Brostjan, Daniela Lötsch, Walter Berger, Johannes A Hainfellner, Ingrid Pabinger, Cihan Ay
Venous thromboembolism (VTE) is common in patients with brain tumors, and underlying mechanisms are unclear. We hypothesized that podoplanin, a sialomucin-like glycoprotein, increases the risk of VTE in primary brain tumors via its ability to induce platelet aggregation. Immunohistochemical staining against podoplanin and intratumoral platelet aggregates was performed in brain tumor specimens of 213 patients (mostly high-grade gliomas [89%]) included in the Vienna Cancer and Thrombosis Study (CATS), a prospective observational cohort study of patients with newly diagnosed cancer or progressive disease aimed at identifying patients at risk of VTE...
January 10, 2017: Blood
https://www.readbyqxmd.com/read/28070669/prospective-cohort-study-of-cancer-patients-diagnosed-with-incidental-venous-thromboembolism-on-routine-computed-tomography-scans
#5
Carmen P Escalante, Gregory W Gladish, Wei Qiao, Ali Zalpour, Binara Assylbekova, Shuwei Gao, Kelechi A Olejeme, Marsha N Richardson, Maria E Suarez-Almazor
PURPOSE: Venous thromboembolism (VTE) is a major complication of cancer with recent increasing reports of incidental VTE. The objectives are to estimate the prevalence of incidental VTE in cancer patients on staging CT scans, identify common symptoms, and determine VTE recurrence in a prospective study. PATIENTS AND METHODS: One thousand ninety patients were studied. Adult cancer patients scheduled for outpatient staging CT scans were eligible. VTE cases were followed for 6 months...
January 9, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28063368/venous-thromboembolism-incidence-recurrence-and-mortality-based-on-women-s-health-initiative-data-and-medicare-claims
#6
Dale R Burwen, Chunyuan Wu, Dominic Cirillo, Jacques E Rossouw, Karen L Margolis, Marian Limacher, Robert Wallace, Matthew Allison, Charles B Eaton, Monika Safford, Matthew Freiberg
INTRODUCTION: Our objective was to compare Medicare claims to physician review and adjudication of medical records for identifying venous thromboembolism (VTE), and to assess VTE incidence, recurrence, and mortality in a large national cohort of post-menopausal women followed up to 19years. MATERIALS AND METHODS: We used detailed clinical data from the Women's Health Initiative (WHI) linked to Medicare claims. Agreement between data sources was evaluated among 16,003 women during 1993-2010...
November 15, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/28062137/direct-oral-anti-coagulants-compared-with-vitamin-k-inhibitors-and-low-molecular-weight-heparin-for-the-prevention-of-venous-thromboembolism-in-patients-with-cancer-a-meta-analysis-study
#7
REVIEW
Natale Daniele Brunetti, Enrico Gesuete, Luisa De Gennaro, Michele Correale, Pasquale Caldarola, Antonio Gaglione, Matteo Di Biase
BACKGROUND: Prior meta-analysis studies showed that direct oral anticoagulants (DOAs) are as effective and safe as warfarin for the prevention of recurrences in patients with venous thrombo-embolism(VTE) and cancer. However, randomized studies also showed that low-molecular-weight-heparin (LMWH) performs better than warfarin in subjects with cancer. We therefore aimed to assess whether, even after pooling data with warfarin and LMWH, the use of DOAs remains safe and effective. METHODS: We performed a meta-analysis of randomized controlled trials with the aim of assessing the efficacy and safety of DOAs in patients with VTE and cancer...
December 27, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28061983/the-use-of-novel-oral-anticoagulants-in-cancer-patients-with-venous-thromboembolism
#8
REVIEW
Stamatis J Karakatsanis, Aikaterini Roumpi, Konstantinos N Syrigos
Venous thromboembolism (VTE) is not uncommon among patients with cancer and is one of the major causes of mortality and morbidity. Treatment with low-molecular-weight heparin (LMWH) is effective, yet accompanied by the need for daily administration of injections for a prolonged time and (even rarely) thrombocytopenia. The discovery of novel oral anticoagulants (NOACs) was based on an effort to improve the pharmacodynamic and pharmacokinetic properties of previous generation anticoagulants while maintaining efficacy without the need for daily subcutaneous administration and frequent laboratory monitoring...
December 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/28054341/intermittent-pneumatic-compression-in-combination-with-low-molecular-weight-heparin-in-the-prevention-of-venous-thromboembolic-events-in-esophageal-cancer-surgery
#9
Kevin Parry, Amir-Hossein Sadeghi, Sylvia van der Horst, Jan Westerink, Jelle P Ruurda, Richard van Hillegersberg
INTRODUCTION: Aim of this study was to evaluate the use of Intermittent Pneumatic Compression (IPC) in the prevention of symptomatic venous thromboembolic events (VTE) in patients undergoing esophagectomy for cancer. METHODS: From a prospective database, all patients operated between 2010 and 2014 received IPC in addition to LMWH and were compared to a historical cohort of patients treated LMWH only (2004-2009). RESULTS: Of the 313 included patients, 195 (62%) received IPC...
January 5, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28052954/clinical-features-and-short-term-outcomes-of-cancer-patients-with-suspected-and-unsuspected-pulmonary-embolism-the-epiphany-study
#10
Carme Font, Alberto Carmona-Bayonas, Carmen Beato, Òscar Reig, Antonia Sáez, Paula Jiménez-Fonseca, Juana M Plasencia, David Calvo-Temprano, Marcelo Sanchez, Mariana Benegas, Mercedes Biosca, Diego Varona, Maria Angeles Vicente, Laura Faez, Maria Del Pilar Solís, Irma de la Haba, Maite Antonio, Olga Madridano, Eduardo Castañon, María Jose Martinez, Pablo Marchena, Avinash Ramchandani, Angel Dominguez, Alejandro Puerta, David Martinez de la Haza, Jesus Pueyo, Susana Hernandez, Angela Fernandez-Plaza, Lourdes Martinez-Encarnacion, Mar Martin, Gema Marin, Francisco Ayala, Vicente Vicente, Remedios Otero
The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary embolism including suspected pulmonary embolism (SPE) and unsuspected pulmonary embolism (UPE) events. Secondary outcomes included 30- and 90-day major bleeding and venous thromboembolism (VTE) recurrence.The study cohort included 1033 consecutive patients with pulmonary embolism from the multicentre observational ambispective EPIPHANY study (March 2006-October 2014). A subgroup of 497 patients prospectively assessed for the study were subclassified into three work-up scenarios (SPE, truly asymptomatic UPE and UPE with symptoms) to assess outcomes...
January 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28052124/prevalence-of-atrial-fibrillation-and-antithrombotic-therapy-in-hemodialysis-patients-cross-sectional-results-of-the-vienna-investigation-of-atrial-fibrillation-and-thromboembolism-in-patients-on-hemodialysis-vivaldi
#11
Oliver Königsbrügge, Florian Posch, Marlies Antlanger, Josef Kovarik, Renate Klauser-Braun, Josef Kletzmayr, Sabine Schmaldienst, Martin Auinger, Günther Zuntner, Matthias Lorenz, Ella Grilz, Gerald Stampfel, Stefan Steiner, Ingrid Pabinger, Marcus Säemann, Cihan Ay
BACKGROUND: Atrial fibrillation (AF) adds significant risk of stroke and thromboembolism in patients on hemodialysis (HD). The aim of this study was to investigate the prevalence of AF in a population-based cohort of HD patients and practice patterns of antithrombotic therapy for stroke prevention in AF. METHODS: The Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemodialysis (VIVALDI), an ongoing prospective observational cohort study, investigates the prevalence of AF and the risk of thromboembolic events in HD patients in Vienna, Austria...
2017: PloS One
https://www.readbyqxmd.com/read/28042112/mobile-pump-deep-vein-thrombosis-prophylaxis-just-say-no-to-drugs
#12
J Haynes, R L Barrack, D Nam
AIMS: The purpose of this article was to review the current literature pertaining to the use of mobile compression devices (MCDs) for venous thromboembolism (VTE) following total joint arthroplasty (TJA), and to discuss the results of data from our institution. PATIENTS AND METHODS: Previous studies have illustrated higher rates of post-operative wound complications, re-operation and re-admission with the use of more aggressive anticoagulation regimens, such as warfarin and factor Xa inhibitors...
January 2017: Bone & Joint Journal
https://www.readbyqxmd.com/read/28039844/low-molecular-weight-heparin-versus-vitamin-k-antagonists-for-the-treatment-of-cancer-associated-thrombosis-a-cost-effectiveness-analysis
#13
Nathan T Connell, Gregory A Abel, Jean M Connors
INTRODUCTION: Cancer-associated venous thromboembolism (VTE) is primarily treated with low-molecular weight heparin (LMWH), a strategy based on studies showing it to be superior to the vitamin K antagonist (VKA) warfarin for preventing VTE recurrence. Subsequent analyses suggest that the magnitude of this benefit might be less than previously determined. Neither patient-focused measures of utility nor the costs of each strategy have been evaluated in the current treatment era. METHODS: This is a cost-effectiveness analysis of VKA and LMWH for the treatment of cancer-associated thrombosis through use of a microsimulation model of outcomes for competing anticoagulation management strategies from a 2014 United States societal perspective...
December 22, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/28029329/tissue-factor-as-a-predictor-of-recurrent-venous-thromboembolism-in-malignancy-biomarker-analyses-of-the-catch-trial
#14
Alok A Khorana, Pieter W Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette S Janas, Mikala F Jarner, Agnes Y Y Lee
Purpose Circulating tissue factor (TF) has been studied as a biomarker for predicting initial, but not recurrent, venous thromboembolism (VTE) in cancer, a setting in which predictors are incompletely understood. We evaluated the association of TF, clinical risk factors, and other biomarkers measured at the time of initial VTE with recurrent VTE in a prespecified analysis of the CATCH (Comparison of Acute Treatments in Cancer Hemostasis) trial. Methods CATCH was a randomized, multicenter trial that investigated tinzaparin 175 IU/kg once daily or dose-adjusted warfarin for 6 months in patients with cancer and acute, symptomatic VTE...
December 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28027659/oral-rivaroxaban-for-the-treatment-of-symptomatic-venous-thromboembolism-in-400-patients-with-active-cancer
#15
Bruno Soriano Pignataro, Kenji Nishinari, Rafael Noronha Cavalcante, Guilherme Centofanti, Guilherme Yazbek, Mariana Krutman, Guilherme Andre Zotelle Bomfim, Igor Yoshio Imagawa Fonseca, Marcelo Passos Teivelis, Nelson Wolosker, Solange Moraes Sanches, Eduardo Ramacciotti
PURPOSE: To study the safety and efficacy of rivaroxaban-a direct oral anticoagulant-use in patients with active cancer and venous thromboembolism (VTE). PATIENTS AND METHODS: Retrospective cohort study of 400 patients with active cancer and associated VTE, defined as deep venous thrombosis and/or pulmonary embolism. This single-center study was carried out from January 2012 to June 2015. The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban...
January 1, 2016: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28012224/continuation-of-low-molecular-weight-heparin-treatment-for-cancer-related-venous-thromboembolism-a-prospective-cohort-study-in-daily-clinical-practice
#16
S J van der Wall, F A Klok, P L den Exter, D Barrios, R Morillo, S C Cannegieter, D Jimenez, M V Huisman
: Essentials Low-molecular-weight heparin (LMWH) injections for venous thromboembolism (VTE) may be burdensome. Patients with active cancer and confirmed VTE were included to evaluate LMWH continuation. The cumulative incidence of discontinuation was 21% after a median period of 90 days. One out of five patients discontinued LMWH injections because of side effects. SUMMARY: Background Current guidelines recommend low -molecular -weight heparin (LMWH) monotherapy for 3-6 months as the first-line treatment for cancer-associated venous thromboembolism (VTE)...
November 5, 2016: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28002372/preoperative-prevalence-of-and-risk-factors-for-venous-thromboembolism-in-patients-with-a-hip-fracture-an-indirect-multidetector-ct-venography-study
#17
Won Chul Shin, Seung Hun Woo, Seung-Jun Lee, Jung Sub Lee, Choongrak Kim, Kuen Tak Suh
BACKGROUND: This retrospective cohort study investigated the prevalence of and risk factors for preoperative venous thromboembolism (VTE) in patients with a hip fracture and a delay of >24 hours from injury to surgery. METHODS: This observational study included 208 patients with a hip fracture surgically treated at 1 university hospital between December 2010 and August 2014. Patients underwent indirect multidetector computed tomographic (MDCT) venography for preoperative VTE detection after admission...
December 21, 2016: Journal of Bone and Joint Surgery. American Volume
https://www.readbyqxmd.com/read/28000388/venous-thromboembolism-in-metastatic-urothelial-carcinoma-or-variant-histologies-incidence-associative-factors-and-effect-on-survival
#18
Jorge D Ramos, Martin F Casey, Simon J Crabb, Aristotelis Bamias, Lauren C Harshman, Yu-Ning Wong, Joaquim Bellmunt, Ugo De Giorgi, Sylvain Ladoire, Thomas Powles, Sumanta K Pal, Guenter Niegisch, Federica Recine, Ajjai Alva, Neeraj Agarwal, Andrea Necchi, Ulka N Vaishampayan, Jonathan E Rosenberg, Matthew D Galsky, Evan Y Yu
Venous thromboembolism (VTE) is common in cancer patients. However, little is known about VTE risk in metastatic urothelial carcinoma or variant histologies (UC/VH). We sought to characterize the incidence, associative factors, including whether various chemotherapy regimens portend different risk, and impact of VTE on survival in metastatic UC/VH patients. Patients diagnosed with metastatic UC/VH from 2000 to 2013 were included in this multicenter retrospective, international study from 29 academic institutions...
December 20, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27999418/impact-of-time-varying-treatment-exposures-on-the-risk-of-venous-thromboembolism-in-multiple-myeloma
#19
Joshua D Brown, Val R Adams, Daniela C Moga
Multiple myeloma (MM) has one of the highest risks of venous thromboembolism (VTE) of all cancers due to pathologic changes and treatment-related exposures. This study assessed the one-year incidence of VTE in newly diagnosed MM and to determine the baseline and time-varying treatment-related factors associated with VTE risk in a U.S.-based cohort. MM patients were identified and age, gender, and baseline comorbidities were determined. Treatment-related exposures included thalidomide derivatives (IMIDs), proteasome inhibitors, cytotoxic chemotherapy, steroids, erythropoietin-stimulating agents (ESAs), stem cell transplants (SCT), hospitalizations, infection, and central venous catheters (CVC)...
December 20, 2016: Healthcare (Basel, Switzerland)
https://www.readbyqxmd.com/read/27992116/predictors-of-active-cancer-thromboembolic-outcomes-validation-of-the-khorana-score-among-patients-with-lung-cancer-comment
#20
S Noble, R Alikhan, A Robbins, F MacBeth, K Hood
We read with interest the article by Mansfield et al. [1] in which the authors report their attempt to validate the Khorana Risk Score (KRS) [2] in the prediction of venous thromboembolism (VTE) amongst ambulant patients with lung cancer, receiving chemotherapy. In their prospectively collected lung cancer database of 719 patients there were 83 (11.5%) episodes of venous thromboembolism (VTE). The incidence of VTE for high risk KRS (score ≥ 3) was 12.4% and for intermediate risk (score 1-2) was 12.1%. This article is protected by copyright...
December 19, 2016: Journal of Thrombosis and Haemostasis: JTH
keyword
keyword
39888
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"